Malaysian Genomics Resource Centre Berhad Past Earnings Performance
Past criteria checks 0/6
Malaysian Genomics Resource Centre Berhad's earnings have been declining at an average annual rate of -9%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 32% per year.
Key information
-9.0%
Earnings growth rate
-5.0%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 32.0% |
| Return on equity | -95.8% |
| Net Margin | -199.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Now An Opportune Moment To Examine Malaysian Genomics Resource Centre Berhad (KLSE:MGRC)?
Mar 02
We Think Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Can Afford To Drive Business Growth
Feb 15Companies Like Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Are In A Position To Invest In Growth
Nov 02Revenue & Expenses BreakdownBeta
How Malaysian Genomics Resource Centre Berhad makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 10 | -19 | 26 | 0 |
| 30 Jun 23 | 8 | -14 | 19 | 0 |
| 31 Mar 23 | 12 | 1 | 10 | 0 |
| 31 Dec 22 | 17 | 6 | 9 | 0 |
| 30 Sep 22 | 23 | 8 | 8 | 0 |
| 30 Jun 22 | 28 | 7 | 8 | 0 |
| 31 Mar 22 | 22 | 1 | 7 | 0 |
| 31 Dec 21 | 19 | -1 | 6 | 0 |
| 30 Sep 21 | 11 | -3 | 6 | 0 |
| 30 Jun 21 | 2 | -4 | 6 | 0 |
| 31 Mar 21 | -3 | -31 | 6 | 0 |
| 31 Dec 20 | -4 | -33 | 7 | 0 |
| 30 Sep 20 | 1 | -7 | 7 | 0 |
| 30 Jun 20 | 1 | -6 | 7 | 0 |
| 31 Mar 20 | 5 | 20 | 6 | 0 |
| 31 Dec 19 | 5 | 21 | 5 | 0 |
| 30 Sep 19 | 0 | -5 | 4 | 0 |
| 30 Jun 19 | 0 | -5 | 5 | 0 |
| 31 Mar 19 | 7 | -4 | 6 | 0 |
| 31 Dec 18 | 13 | -5 | 9 | 0 |
| 30 Sep 18 | 20 | -5 | 11 | 0 |
| 30 Jun 18 | 26 | -5 | 13 | 0 |
| 31 Mar 18 | 23 | -3 | 13 | 0 |
| 31 Dec 17 | 18 | -1 | 11 | 0 |
| 30 Sep 17 | 13 | -1 | 10 | 0 |
| 30 Jun 17 | 10 | 1 | 8 | 0 |
| 31 Mar 17 | 9 | 0 | 7 | 0 |
| 31 Dec 16 | 9 | 1 | 7 | 0 |
| 30 Sep 16 | 10 | 2 | 7 | 0 |
| 30 Jun 16 | 10 | 2 | 7 | 0 |
| 31 Mar 16 | 12 | 2 | 8 | 0 |
| 31 Dec 15 | 14 | 3 | 9 | 0 |
| 30 Sep 15 | 15 | 4 | 9 | 0 |
| 30 Jun 15 | 14 | 4 | 9 | 0 |
| 31 Mar 15 | 13 | 3 | 9 | 0 |
| 31 Dec 14 | 9 | 0 | 9 | 0 |
| 30 Sep 14 | 6 | -2 | 9 | 0 |
| 30 Jun 14 | 4 | -4 | 9 | 0 |
| 31 Mar 14 | 3 | -6 | 8 | 0 |
| 31 Dec 13 | 2 | -6 | 8 | 0 |
| 30 Sep 13 | 1 | -8 | 9 | 0 |
| 30 Jun 13 | 1 | -9 | 9 | 0 |
Quality Earnings: MGRC is currently unprofitable.
Growing Profit Margin: MGRC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MGRC is unprofitable, and losses have increased over the past 5 years at a rate of 9% per year.
Accelerating Growth: Unable to compare MGRC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MGRC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.4%).
Return on Equity
High ROE: MGRC has a negative Return on Equity (-95.75%), as it is currently unprofitable.